

PSORIASIS ASSOCIATED WITH HIDRADENITIS SUPPURATIVA: A LARGE SCALE WORLDWIDE POPULATION-BASED STUDY

B. Halioua¹, C. Le Roux-Villet², M. Saint Aroman³, Y. Ben Hayoun⁴, C. Taieb⁵, M.-F. Bru⁶, C. Baissac³, C. Skayem^{7, 8}, M.-A. Richard^{9, 10}

¹ Centre de dermatologie, Paris, France ² Dermatologie, Hôpital Avicenne AP-HP, Centre de référence MALIBUL, Groupe Bulles de la SFD, Bobigny, France ³ Pierre Fabre, Patient centricity, Toulouse, France ⁴ EMMA, Data Scientist, Tel Aviv, Israël ⁵ EMMA, Patients priority, Paris, France ⁶ Association Française pour la Recherche sur l'Hidrosadénite, Patient Expert, Ile de la Réunion, France ⁷ Sorbonne University, Faculty of medecine, Paris, France ⁸ Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré, Department of Dermatology, Boulogne Billancourt, France ⁹ Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Department of Dermatology, Marseille, France ¹⁰ Société Française de Dermatologie, HS France, Paris, France

Disclosure Information:

Abbvie,
UCB,
Leo Pharma,
Lilly,
Novartis,
Almirall,
Pierre Fabre,
La Roche Posay

Commercial Support Information:

As part of the ALL [All Skins, All colors, All dermatoses] project, this work was funded by Patient Centricity by Pierre Fabre, France





Introduction


- The coexistence of psoriasis and Hidradenitis suppurativa (HS) has been revealed in several case reports and case series^(1,2)suggesting a causal relationship
- Epidemiological evidence of an association between these diseases is still lacking.
- No informations about racial and ethnic disparities in HS associated with psoriasis.
- The ALL PROJECT aims at providing a snapshot state of the prevalence of HS in patients with psoriasis compared to individuals with psoriasis, HS and control subjects.

Material and methods

20 COUNTRIES FOR OVER 50% OF THE WORLD'S POPULATION!

Online survey of the general population over 16 years of age in 20 countries worldwide.

- Demographic and socio-demographic profiles
- Optional report ethnic and racial origin
- Self-reported Fitzpatrick skin phototypes
- Presence of a dermatological condition occurring in the past year



Material and methods

- Hidradenitis suppurativa reported by the patients on the basis of a diagnosis by a doctor
- Patients who reported feelings of stigmatization (FS) if because of their HS.
 - => they felt that they were ostracized or rejected by others
 - => and/or that they felt that they were looked at with disgust
 - => and/or that people avoided touching them
 - => and/or that people avoided approaching them

Four groups :

African descent with Fitzpatrick skin phototype (FSP) V-VI (AD)

Caucasian descent with Fitzpatrick skin types 1-3 (C)


East Asian cohort from China and South Korea (EA)

Indian cohort (I) from India





n=27175 Males 14674 (54%) / Females 12591 (46%) Mean age 44.7 +/-15.7 yrs



HS associated with Psoriasis N=115 (0.4%)

Psoriasis isolated n= 1646 (6.1%) HS isolated n= 328 (1,2%) Control n=25086 (92.3%)



Prevalence HS in patients with psoriasis(6.5%)

Prevalence HS in the control group (1.2%)

High prevalence in Indians 27.4% ++++

Asians (27.4% vs 6.5%; P < .001)

Africans (27.4% vs 6.8%; P < .001)

Caucasians (27.4% vs3.5%; P <.001

	% HS Psoriasis	% HS control	RR	IC à 95 % :	р
Total	115/1761(6.5%)	328 /25414(1,3%)	5.34	4.29 -6.64	< 0.001
Africans	5/74(6.8%)	34/1923(1,8%)	4.02	1,52 -10,61	0,0048
Asians	22/400(5.5%)	48/4246(1,1%)	5.09	3,03- 8,52	< 0,0001
Caucasians	39/1108(3.5%)	170/17639(1,0%)	3.74	2,63- 5,33	<0,0001
Indians	49/179(27.4%)	76/11606(4,7%)	7,58	5.08-11.33	<0,0001

Results

Age HS+PSO

Mean age HS + psoriasis

< psoriasis (37.1 vs 45.1 P < .005)</pre>

< HS (37.1 vs 39.9 years, P < .001).

++++ Caucasians

Except Indians Asians and Africans NS

Mean age HS+Psoriasis


Asians > Africans, Indians and Caucasians

	% HS obeses	% HS NO obeses	RR	IC à 95 % :	р
Total	60/12501 (0.5%)	55/14674 (0.4%)	1.28	0,88 to 1,84	0,18
Africans	0/799 (0%)	5/1198 (0.4%)	0.13	0.007 to 2.46	0.17
Asians	15/2136 (0.7%)	7/2510 (0.3%)	2.51	1,02 à 6,18	0,04
Caucasians	14/8774 (0.2%)	25/9973 (0.2%)	0.63	0,33 à 1,22	0,17
Indians	31/792 (3.9%)	18/993 (1.8%)	2.15	1,19 à 3,88	0,01

		ZH	Psoriasis isolated	HS associated with psoriasis	
	Total	n=27165	39.9+/-13.6	45.1+/15.4	37.1+/-15.7
	Africans	n=1987	31.08+/15/7	31+/-14.3	31+/-13.3
	Asians	n=4646	39.9+/15.7	44.4+/-14.3	44.9+/-15.1
	Caucasians	n=18747	41.9+/-15.8	47.3+/-15.8	33.6+/-11.4
	Indians	n=1785	39.2+/-12.3	36.8+/-12.5	36.9+/-11.7


SEX HS+PSO

Female predominance of Asian and Indian HS+psoriasis



Results

Smoking not a risk factor for HS+psoriasis (1.0% vs 1.5% p 0.26)



	%HS+ psoriasis Obesity	%HS+ psoriasis Non obesity	RR	IC à 95 % :	р
Total	20/3603 (0.6%)	91/18492 (0.5%)	1.12	0.69 to 1.83	0.62
Africans	1/300 (0,3%)	3/1155 (0.3%)	1.28	0.13 to 12.38	0.82
Asians	8/277 (2.9%)	14/277 (0.4%)	7.20	2.99 to 17.32	0.0001
Caucasians	6/2863 (0,2%)	30/11978 (0.3%)	0.83	0.34 to 2.01	0.69
Indians	5/163 (3.1%)	44/1416 (3.1%)	0.98	0.38 to 2.52	0.97

	%HS+ psoriasis Smoking	%HS+ psoriasis non smoking	RR	IC à 95 % :
Total	108/11200 (1.0%)	7/470 (1.5%)	0.64	0.2998 to 1.39
Africans	4/1014 (0.4%)	1/36 (2.7%)	0.14	0.0155 to 1.30
Asians	22/2567 (0.8%)	0/29 (0%)	0.51	0.0306 to 8.72
Caucasians	39/6741 (0.6%)	0/95 (0%)	1.11	0.0683 to 18.34
Indians	43/878 (4.7%)	7/312 (2.2%)	2.18	0.9718 to 4.90

Obesity (BMI >= 30) (%) is not a risk factor for HS+psoriasis (0.6% vs 0.5% p:0.62) except in Asians populations

Conclusion

- We have established a significant prevalence of HS in patients suffering from psoriasis (6.5%), with a higher prevalence in Indians populations (27.4%).
- Further studies are needed to gain a better understanding of the relationship between these two chronic inflammatory dermatoses, which share aetiopathogenic links, notably increased secretion of IL-12/23 and TNF α .
- Further studies are needed to assess the extent of the burden and impairment of quality of life associated with the co-occurrence of HS and psoriasis.
- Psoriasis should be considered as a comorbidity of HS, which requires screening and appropriate management.